Chemotherapy-induced gabapentin

Observational studies In an open study in 75 patients with chemotherapy-induced neuropathic pain, gabapentin monotherapy 800 mg/day caused mild somnolence in about 25%, but none stopped taking the drug [106 =]. 

Tsavaris N, Kopterides P, Kosmas C, Efthymiou A, Skopelitis H, Dimitrakopoulos A, Pagouni E, Pikazis D, Zis PV, Koufos C. Gabapentin monotherapy for the treatment of chemotherapy-induced neuropathic pain a pilot study. Pain Med 2008 9(8) 1209-16. 

Placebo-controlled studies The efficacy and safety of gabapentin for prevention of chemotherapy-induced nausea and vomiting were evaluated [67 ]. Chemotherapy-naive patients received either placebo or gabapentin 300-900 mg/d, 5 days prior to xmtil 5 days after chemotherapy. One patient stopped gabapentin treatment due to sleepiness. Other side effects related to gabapentin included xerostomia (57%), weakness (47%), sleepiness (45%), dizziness (45%), constipation (45%), and heart bum (32.5%). There were no significant differences in incidence of side effects between treatment and control groups in tiiis study. 

Cruz FM, de Iracema Gomes Cubero D, Taranto P, Lemer T, Lera AT, da Costa Miranda M, et al. Gabapentin for the prevention of chemotherapy- induced nausea and vomiting a pilot study. Support Care Cancer March 2012 20(3) 601-6. 

---